Quality control system of the endoplasmic reticulum and related diseases

Acta Biochimica et Biophysica Sinica

Volumn 38, Issue 4, 2006, Pages 219-226

  Wu, Jun Chao ^a   Liang, Zhong Qin ^a   Qin, Zheng Hong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Calnexin calreticulin cycle; Endoplasmic reticulum associated degradation; Protein folding; Protein misfolding disease; Quality control

Indexed keywords

CALNEXIN; CALRETICULIN; CHAPERONE; PROTEIN;

ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM; HUMAN; HUNTINGTON CHOREA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PRION DISEASE; PROTEIN FOLDING; SHORT SURVEY;

ALZHEIMER DISEASE; ANIMALS; CALNEXIN; CALRETICULIN; ENDOPLASMIC RETICULUM; HUMANS; HUNTINGTON DISEASE; MOLECULAR CHAPERONES; NEURODEGENERATIVE DISEASES; PRION DISEASES; PROTEIN FOLDING; PROTEINS;

EID: 33646061642     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2006.00156.x     Document Type: Short Survey

References (46)

1. Tu BP Weissman JS. Oxidative protein folding in eukaryotes: Mechanisms and consequences. J Cell Biol 2004 164 341 346.
2. Kleizen B Braakman I. Protein folding and quality control in the endoplasmic reticulum. Curr Opin Cell Biol 2004 16 343 349.
3. Thomas PJ Qu BH Pedersen PL. Defective protein folding as a basis of human disease. Trends Biochem Sci 1995 20 456 459.
4. Qin ZH Wang Y Sapp E Cuiffo B Wanker E Hayden MR Kegel KB et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 2004 24 269 281.
5. Perlmutter DH. Liver injury in alpha 1-antitrypsin deficiency: An aggregated protein induces mitochondrial injury. J Clin Invest 2002 110 1579 1583.
6. Ellgaard L Molinari M Helenius A. Setting the standards: Quality control in the secretory pathway. Science 1999 286 1882 1888.
7. Guo L Groenendyk J Papp S Dabrowska M Knoblach B Kay C Parker JM et al. Identification of an N-domain histidine essential for chaperone function in calreticulin. J Biol Chem 2003 278 50645 50653.
8. 2+ signaling and calcium binding chaperones of the endoplasmic reticulum. Cell Calcium 2002 32 269 278.
9. Michalak M Lynch J Groenendyk J Guo L Robert Parker JM Opas M. Calreticulin in cardiac development and pathology. Biochim Biophys Acta 2002 1600 32 37.
10. High S Lecomte FJ Russell SJ Abell BM Oliver JD. Glycoprotein folding in the endoplasmic reticulum: Atale of three chaperones FEBS Lett 2000 476 38 41.
11. Trombetta ES Parodi AJ. Quality control and protein folding in the secretory pathway. Annu Rev Cell Dev Biol 2003 19 649 676.
12. Roth J Ziak M Zuber C. The role of glucosidase II and endomannosidase in glucose trimming of asparagine-linked oligosaccharides. Biochimie 2003 85 287 294.
13. Shen X Zhang K Kaufman RJ. The unfolded protein response - a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat 2004 28 79 92.
14. Knee R Ahsan I Mesaeli N Kaufman RJ Michalak M. Compromised calnexin function in calreticulin-deficient cells. Biochem Biophys Res Commun 2003 304 661 666.
15. Ellgaard L Riek R Herrmann T Guntert P Braun D Helenius A Wuthrich K. NMR structure of the calreticulin P-domain. Proc Natl Acad Sci USA 2001 98 3133 3138.
16. Schrag JD Bergeron JJ Li Y Borisova S Hahn M Thomas DY Cygler M. The structure of calnexin, an ER chaperone involved in quality control of protein folding. Mol Cell 2001 8 633 644.
17. Molinari M Helenius A. Chaperone selection during glycoprotein translocation into the endoplasmic reticulum. Science 2000 288 331 333.
18. Bottomley MJ Batten MR Lumb RA Bulleid NJ. Quality control in the endoplasmic reticulum: PDI mediates the ER retention of unassembled procollagen C-propeptides. Curr Biol 2001 11 1114 1118.
19. Sitia R Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 2003 426 891 894.
20. Selkoe DJ. Folding proteins in fatal ways. Nature 2003 426 900 904.
21. Bernier V Lagace M Bichet DG Bouvier M. Pharmacological chaperones: Potential treatment for conformational diseases. Trends Endocrinol Metab 2004 15 222 228.
22. Conn PM Leanos-Miranda A Janovick JA. Protein origami: Therapeutics rescue of misfolded gene products. Mol Interv 2002 2 308 316.
23. Perlmutter DH. Chemical chaperones: A pharmacological strategy for disorders of protein folding and trafficking. Pediatr Res 2002 52 832 836.
24. Bernier V Bichet DG Bouvier M. Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol 2004 4 528 533.
25. Kim BE Smith K Meagher CK Petris MJ. A conditional mutation affecting localization of the Menkes disease copper ATPase. Suppression by copper supplementation. J Biol Chem 2002 277 44079 44084.
26. Frustaci A Chimenti C Ricci R Natale L Russo MA Pieroni M Eng CM et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001 345 25 32.
27. Morello JP Petäjä-Repo UE Bichet DG Bouvier M. Pharmacological chaperones: Anew twist on receptor folding. Trends Pharmacol Sci 2000 21 466 469.
28. Sharma M Pampinella F Nemes C. Benharouga M So J Du K Bache KG et al. Misfolding diverts CFTR from recycling to degradation: Quality control at early endosomes. J Cell Biol 2004 164 923 933.
29. Le A Steiner JL Ferrell GA Shaker JC Sifers RN. Association between calnexin and a secretion-incompetent variant of human ? 1-antitrypsin. J Biol Chem 1994 269 7514 7519.
30. Lord JM Davey J Frigerio L Roberts LM. Endoplasmic reticulum-associated protein degradation. Semin Cell Dev Biol 2000 11 159 164.
31. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001 2 169 178.
32. Schmitz A Herzog V. Endoplasmic reticulum-associated degradation: Exceptions to the rule. Eur J Cell Biol 2004 83 501 509.
33. Drenth JP Martina JA van de Kerkhof R Bonifacino JS Jansen JB. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med 2005 11 37 42.
34. Bonini NM. Chaperoning brain degeneration. Proc Natl Acad Sci USA 2002 99 16407 16411.
35. Hershko A Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998 67 425 479.
36. Glickman MH Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002 82 373 428.
37. De Vrij FM Fischer DF van Leeuwen FW Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 2004 74 249 270.
38. QIN ZH GU ZL Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin 2004 25 1243 1249.
39. Cascio P Call M Petre BM Walz T Goldberg AL. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO J 2002 21 2636 2645.
40. Whitby FG Masters EI Kramer L Knowlton JR Yao Y Wang CC Hill CP. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 2000 408 115 120.
41. Rivett AJ Bose S Brooks P Broadfoot KI. Regulation of proteasome complexes by γ-interferon and phosphorylation. Biochimie 2001 83 363 366.
42. Teoh CY Davies KJ. Potential roles of protein oxidation and the immunoproteasome in MHC class I antigen presentation: The 'PrOxI' hypothesis. Arch Biochem Biophys 2004 423 88 96.
43. Diaz-Hernandez M Hernandez F Martin-Aparicio E Gomez-Ramos P Moran MA Castano JG Ferrer I et al. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 2003 23 11653 11661.
44. Ding Q Lewis JJ Strum KM Dimayuga E Bruce-Keller AJ Dunn JC Keller JN. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J Biol Chem 2002 277 13935 13942.
45. Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci 2001 24 519 550.
46. Chiesa R Harris DA. Prion diseases: What is the neurotoxic molecule Neurobiol Dis 2001 8 743 763.